Since tofacitinib, a JAK1 and JAK3 kinase inhibitor, targets multiple cytokine receptors and exhibits diverse in vitro effects [49, 50], we postulate that seronegative RA patients might share a common pathology with the JAK pathway that could be targeted by tofacitinib. Here, JAK3 is linked to rheumatoid arthritis.